SEOUL, Oct. 31 (Korea Bizwire) – Domestic pharmaceutical firms have started to release sensitive information that may play to their disadvantage, mainly in order to eliminate any misunderstanding or speculation by not disclosing information in advance. The move is also driven by the recent Hanmi Pharmaceutical controversy, in which the company allegedly leaked insider information [...]
SEOUL, Oct. 25 (Korea Bizwire) – Korean pharmaceutical companies are making significant developments in their research of Parkinson’s disease. Parkinson’s is often associated with the elderly, making Korea’s rapidly-aging society more vulnerable to the disease, for which there is no cure. Dong-A ST is set to apply for a phase 2 clinical trial for the [...]
SEOUL, Oct. 20 (Korea Bizwire) – Six residency programs, including urology and cardiothoraic surgery, have failed to meet 70 percent of their enrollment quota for medical students this year, a report showed Thursday, raising the need for more incentives to attract students to the less popular residency programs. No medical student applied for the tuberculosis [...]
SEOUL, Oct. 17 (Korea Bizwire) – The current news proves that the domestic pharmaceutical industry still places too much emphasis on generics, despite focusing on R&D for new medicine. With the expiration of the patent for Twynsta from the multinational pharmaceutical company Boehringer Ingelheim, close to 100 generics are being released. The industry agrees that [...]
SEOUL, Sept. 21 (Korea Bizwire) – C&C Research Laboratories (CCRL), a joint pharmaceutical venture between South Korea and Japan, announced Monday that it will finally begin its development processes for atopy and breast cancer medicines. CCRL was established in 1992 as a 50-50 joint venture between Korea’s JW Pharmaceutical and Chugai Pharmaceutical in Japan. It [...]
SEOUL, Aug. 1 (Korea Bizwire) – The American dollar has regained some strength in the second quarter, and according to industry analysts, companies producing chemicals and raw materials for the pharmaceutical industry were among those who reaped the most benefits from the dollar’s appreciation. Korea is a heavily export-reliant country with over 50 percent of [...]
SEOUL, June 9 (Korea Bizwire) – Controversy has flared up over South Korean authorities’ recent approval of a new drug that premises to treat both high blood pressure and erectile dysfunction. In early May, the Ministry of Food and Drug Safety gave the green light to the antihypertensive and anti-impotence medicine developed by Hanmi Pharmaceutical [...]
SEOUL, May 26 (Korea Bizwire) – A total of 297,000 foreigners visited South Korea for medical purposes in 2015, up 11 percent from 267,000 a year ago, the Ministry of Health and Welfare said Thursday. Their medical expenditures jumped 20 percent on-year to 670 billion won (US$567.3 million), with one-third of the amount coming from [...]
SEOUL, May 24 (Korea Bizwire) – Recent anticipation predicts that Korea’s biosimilar market will grow to a 150-billion-won industry by 2019. According to the Korea Pharmaceutical Manufacturers Association (KPMA), the industry, which was valued at 80 billion won in 2013, will grow to a 150 billion won market by 2019. The government’s active policy towards biosimilars, [...]
SEOUL, May 11 (Korea Bizwire) – Korean pharmaceutical and biotech companies are rushing to conduct Phase I clinical trials. Phase 1 trials are the first step in human testing of new drugs, and they’re the first step in new drug development. According to the Ministry of Food and Drug Safety, a total of 64 Phase [...]